Endocrinology - Global Cardiology Academy

1-16 of 18

Supporting Whole-Body Health Through the Gut
Supporting Whole-Body Health Through the Gut
NutritionEdge
Supporting Whole-Body Health Through the Gut
Shelina Ramnarine, PhD; Terri DeNeui, DNP, APRN, ACNP-BC
- Shelina Ramnarine, PhD
- Terri DeNeui, DNP, APRN, ACNP-BC
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
Heart Matters
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
Brian P. McDonough, MD, FAAFP; Anu Lala, MD
- Brian P. McDonough, MD, FAAFP
- Anu Lala, MD
- Martha Gulati, MD, MS, FACC, FAHA
Hypertension Across Diverse Populations: Practical Strategies for Equitable Care
Hypertension Across Diverse Populations: Practical Strategies for Equitable Care
Heart Matters
Hypertension Across Diverse Populations: Practical Strategies for Equitable Care
Alexandria May, PharmD, BCPS; Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
- Alexandria May, PharmD, BCPS
- Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
Cardiometabolic Considerations in Familial Chylomicronemia Syndrome
Cardiometabolic Considerations in Familial Chylomicronemia Syndrome
On the Frontlines of Familial Chylomicronemia Syndrome
Cardiometabolic Considerations in Familial Chylomicronemia Syndrome
Steve Jackson, PharmD; Robert H. Eckel, MD, FAHA, FACC, FNLA
- Steve Jackson, PharmD
- Robert H. Eckel, MD, FAHA, FACC, FNLA
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CE
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
Richard E. Pratley, MD; David Cherney, MD, PhD
0.50 credits
- Richard E. Pratley, MD
- David Cherney, MD, PhD
- prof. Hiddo Heerspink
0.50 credits
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Heart Matters
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Susan Davis
- Susan Davis
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Nephrology
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Richard E. Pratley, MD
- Richard E. Pratley, MD
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Nephrology
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Nephrology
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
prof. Hiddo Heerspink
- prof. Hiddo Heerspink
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
Nephrology
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
prof. Hiddo Heerspink
- prof. Hiddo Heerspink
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
CME/CE
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
prof. Hiddo Heerspink; Peter Rossing, MD, DMSc
0.50 credits
- prof. Hiddo Heerspink
- Peter Rossing, MD, DMSc
- Paola Fioretto, MD
0.50 credits
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
CME/CE
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
Rajiv Agarwal, MBBS, MD, FASN, BRCU; Prof. Dr. Francesc Xavier Cos Claramunt
0.25 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Prof. Dr. Francesc Xavier Cos Claramunt
0.25 credits
Optimizing Patient Outcomes in CKD & T2D Care With CONFIDENCE
Optimizing Patient Outcomes in CKD & T2D Care With CONFIDENCE
Endocrinology
Optimizing Patient Outcomes in CKD & T2D Care With CONFIDENCE
Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
CKM Syndrome Linked to Heart, Kidney, and Metabolic Diseases
CKM Syndrome Linked to Heart, Kidney, and Metabolic Diseases
Heart Matters
CKM Syndrome Linked to Heart, Kidney, and Metabolic Diseases
Anticipated Updates on Statin Intolerance at ACC 2023
Anticipated Updates on Statin Intolerance at ACC 2023
ACC Action Center
Anticipated Updates on Statin Intolerance at ACC 2023
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA; Kevin C. Maki, PhD, FNLA, CLS
- Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
- Kevin C. Maki, PhD, FNLA, CLS
What to Know About the No Surprises Act
What to Know About the No Surprises Act
Perspectives with the AMA
What to Know About the No Surprises Act
Charles Turck, PharmD, BCPS, BCCCP; Emily Carroll, JD, MSW
- Charles Turck, PharmD, BCPS, BCCCP
- Emily Carroll, JD, MSW

Prev
1
2
Next

1/2